Aug 31 2023 |
et al., Circulation, doi:10.1161/CIRCULATIONAHA.123.065190 | Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial |
| 33% higher mortality (p=0.24) and 43% worse results (p=0.16). RCT 422 hospitalized COVID-19 patients showing no significant difference in mortality or organ support-free days with crizanlizumab, a P-selectin inhibitor. There was a trend towards increased mortality with crizanlizumab. The study was s.. | ||
Dec 31 2021 |
et al., JACC: Basic to Translational Science, doi:10.1016/j.jacbts.2021.09.013 | Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19 |
| 35% lower hospital discharge (p=0.16). RCT 54 hospitalized COVID-19 patients showing crizanlizumab treatment reduced soluble P-selectin levels, increased D-dimer levels, and decreased prothrombin fragment 1.2 compared to placebo. There were no significant differences in inflam.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.